Valuation: HLS Therapeutics Inc.

Market Cap 94.77M 83.12M 76.74M 70.92M 134M 9.07B 137M 923M 358M 4.44B 356M 348M 15.42B P/E 2026 *
-15.2x
P/E 2027 * -101x
Enterprise Value 94.77M 83.12M 76.74M 70.92M 134M 9.07B 137M 923M 358M 4.44B 356M 348M 15.42B EV / Sales 2026 *
1.63x
EV / Sales 2027 * 1.47x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 day-5.06%
1 month-4.76%
6 months-12.54%
Current year-12.54%
1 month 2.98
Extreme 2.98
3.16
Current year 2.98
Extreme 2.98
3.44
1 year 2.98
Extreme 2.98
4.02
3 years 2.22
Extreme 2.22
4.94
5 years 2.22
Extreme 2.22
16.44
10 years 0
Extreme 0
19.1
Manager TitleAgeSince
Chief Executive Officer 58 2023-04-30
Director of Finance/CFO 61 2024-01-25
Chief Tech/Sci/R&D Officer 61 2014-05-31
Director TitleAgeSince
Director/Board Member 58 2018-03-11
Chairman 48 2023-06-21
Director/Board Member 65 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-5.06%-.--% - - 94.77M
+1.40%+6.59%+13.06%+97.38% 94.52B
-1.07%-0.24%+44.21%+153.12% 56.14B
-0.71%+1.82%-7.28%+241.46% 22.5B
0.00%+4.94%-9.97%-24.94% 8.04B
-1.03%+2.88%-27.02%-36.57% 7.54B
+0.94%+7.98%-7.24%-27.97% 6.77B
-0.50%+1.35%+22.72%+35.22% 6.42B
-0.46%+1.83%-1.60%+22.17% 5.35B
+1.21%+6.82%-3.28%-6.33% 3.63B
Average -0.51%+2.63%+2.62%+50.39% 23.44B
Weighted average by Cap. +0.54%+3.05%+15.86%+108.52%

Financials

2026 *2027 *
Net sales 58.03M 50.9M 46.99M 43.42M 82.3M 5.56B 83.95M 565M 219M 2.72B 218M 213M 9.44B 64.31M 56.41M 52.08M 48.12M 91.22M 6.16B 93.04M 626M 243M 3.01B 242M 236M 10.46B
Net income -6.26M -5.49M -5.07M -4.69M -8.89M -600M -9.06M -60.98M -23.69M -294M -23.53M -23.01M -1.02B -1.05M -921K -850K -786K -1.49M -101M -1.52M -10.22M -3.97M -49.2M -3.94M -3.86M -171M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.030USD
Average target price
5.179USD
Spread / Average Target
+70.91%

Quarterly revenue - Rate of surprise